Tumor necrosis factor-α-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-κB by an IκBα 'super-repressor'

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1969-1977

  Muenchen, Heather J ^a   Lin, Din Lii ^b   Walsh, Michael A ^a   Keller, Evan T ^b   Pienta, Kenneth J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOPLASM PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER RECURRENCE; CELL ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; APOPTOSIS; BIOLOGICAL TRANSPORT; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B PROTEINS; INTERLEUKIN-6; MALE; MUTATION; NF-KAPPA B; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034026354     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Helson, L., Helson, C., and Green, S. Effect of murine tumor necrosis factor on heterotransplanted human tumors. Exp. Cell. Biol., 47: 53-60, 1979.
2. Watanabe, N., Niitsu, Y., Umeno, H., Sone, H., and Neda, H. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res., 48: 2179-2183, 1988.
3. Muenchen, H., and Aggarwal, S. Enhanced immune system activation after treatment with novel antineoplastic platinum agents. Anticancer Res., 18: 2631-2636, 1998.
4. Claudio, E., Segade, F., Wrobel, K., Ramos, S., and Bravo, R. Molecular mechanisms of TNF-α cytotoxicity: activation of NF-κB and nuclear translocation. Exp. Cell Res., 224: 63-71, 1996.
5. Laster, S. M., Wood, J. G., and Gooding, C. R. Target-induced changes in macrophage migration may explain differences in lytic sensitivity among simian virus 40-transformed fibroblasts. J. Immunol., 141: 2629-2635, 1988.
6. Muenchen, H., Aggarwal, S., Misra, H., and Andrulis, P. Enhanced immunostimulation by novel platinum anticancer agents. Anticancer Drugs, 8: 323-328, 1997.
7. Muenchen, H., and Aggarwal, S. Activation of murine peritoneal macrophages after cisplatin and taxol combination. Anticancer Drugs, 8: 784-789, 1997.
8. Sugarman, B. J., Aggarwal, B. B., Hass, P. E., Figary, I. E., Palladino, M. A., and Shepard, H. M. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science (Washington DC), 230: 943-945, 1985.
9. Nakashima, J., Tachibana, M., Ueno, M., Miyajima, A., and Baba, S. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin. Cancer Res., 4: 1743-1748, 1998.
10. Irie, A., Lee, K., Kadowaki, K., Toda, K., and Yamada, Y. Elevation of serum and urine tumor necrosis factor levels after transurethral resection of the prostate. Nippon Hinyokika Gakkai Zasshi, 90: 502-508, 1999.
11. Nakashima, J., Tachibana, M., Ueno, M., Baba, S., and Tazaki, H. Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res., 55: 4881-4885, 1995.
12. Akdas, A., Turkeri, L., and Akoglu, T. Serum and urine levels of tumour necrosis factor in patients with genitourinary cancer and their relevance to disease status. Int. Urol. Nephrol., 22: 501-506, 1990.
13. Nakajima, Y., Dellipizzi, A., Mallouh, C., and Ferreri, N. TNF-mediated cytotoxicity and resistance in human prostate cancer cell lines. Prostate, 29: 296-302, 1996.
14. Soares, M., Muniappan, A., Kaczmarek, E., Koziak, K., and Wrighton, C. Adenovirus-mediated expression of a dominant negative mutant of p65/RelA inhibits proinflammatory gene expression in endothelial cells without sensitizing to apoptosis. J. Immunol., 161: 4572-4582, 1998.
15. Barnes, P. J., and Karin, M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med., 336: 1066-1071, 1997.
16. Douherty, G. J., Murdoch, S., and Hogg, N. The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response. Eur. J. Immunol., 18: 35-39, 1988.
17. Kurokouchi, K., Kambe, F., Yasukawa, K., Izumi, R., and Ishiguro, N. TNF-α increases expression of IL-6 and ICAM-1 genes through activation of NF-κB in osteoblast-like ROS17/2.8 cells. J. Bone Miner. Res., 13: 1290-1299, 1998.
18. Ikebe, T., Takeuchi, H., Jimi, E., Beppu, M., and Shinohara, M. Involvement of proteosomes in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma. Int. J. Cancer, 77: 578-585, 1998.
19. Baeuerle, P., and Baltimore, D. A 65-kD subunit of NF-κB is required for inhibition of NF-κB by IκB. Genes Dev., 3: 1689-1698, 1989.
20. Hellerbrand, C., Jobin, C., Iimuro, Y., Licato, L., Balfour Sartor, R., and Brenner, D. A. Inhibition of NFκB in activated rat hepatic stellate cells by proteosome inhibitors and an IκB super-repressor. Hepatology, 27: 1285-1295, 1998.
21. Jobin, C., Panja, A., and Hellerbrand, C. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor κB super-repressor in human intestinal epithelial cells. J. Immunol., 160: 410-418, 1998.
22. Ballard, D., Dixon, E., Peffer, N., Bogerd, H., and Doerre, S. The 65-kDa subunit of human NF-κB functions as a potent transcriptional activator and a target for v-Rel-mediated repression. Proc. Natl. Acad. Sci. USA, 89: 1875-1879, 1992.
23. Baeuerle, P., and Baltimore, D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor. Cell, 53: 211-217, 1988.
24. Brockman, J., Scherer, D., Mckinsey, T., Hall, S., and Qi, X. Coupling of a signal response domain in IκBα to multiple pathways for NF-κB activation. Mol. Cell. Biol., 15: 2809-2818, 1995.
25. Regnier, C., Song, H. Y., Gao, X., Goeddel, G. V., Cao, Z., and Rothe, M. Identification and characterization of an Iκ B kinase. Cell, 90: 373-383, 1997.
26. Beg, A. A., Finco, T. S., Nantermet, P. V., and Baldwin, A. S., Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of Iκ Bα: a mechanism for NF-κB activation. Mol. Cell. Biol., 13: 3301-3310, 1993.
27. Kitamura, M. Adoptive transfer of nuclear factor-κB-inactive macrophages to the glomerulus. Kidney Int., 57: 709-716, 2000.
28. Pajonk, F., Pajonk, K., and McBride, W. Inhibition of NF-κB, clonogenicity, and radiosensitivity of human cancer. J. Natl. Cancer Inst., 91: 1956-1960, 1999.
29. Li, N., and Karin, M. Ionizing radiation and short wavelength UV activate NF-κB through two mechanisms. Proc. Natl. Acad. Sci. USA, 95: 13012-13017, 1998.
30. Brown, K., Gersberger, S., Carlson, L., Franzoso, G., and Siebenlist, U. Control of IkB-α proteolysis by site-specific, signal-induced phosphorylation. Science (Washington DC), 267: 1485-1488, 1995.
31. van Hogerlindin, M., Rozell, B., Ahrlund-Richter, L., and Toftgard, R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-κB signaling. Cancer Res., 59: 3299-3303, 1999.
32. Miagkov, A., Kovalenko, D., Brown, C., Didsbury, J., Cogswell, J., Stimpson, S., Baldwin, A., and Makarov, S. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl. Acad. Sci. USA, 95: 13859-13864, 1998.
33. Didonato, J., Mercurio, F., Rosette, C., Wu-Li, J., Suyang, H., Ghosh, S., and Karin, M. Mapping of inducible IκB phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell. Biol., 16: 1295-1304, 1996.
34. Imamura, K., Sherman, M. L., Sprigg, D., and Kufe, D. Effect of tumor necrosis factor on GTP binding and GTPase activity in HL-60 and L929 cells. J. Biol. Chem., 263: 10247-10253, 1988.
35. Miele, L., Cordella-Miele, E., and Mukherjee, A. B. Novel anti-inflammatory peptides from the region of highest similarity between uteroglobin and lipocortin I. Nature (Lond.), 335: 726-730, 1988.
36. De Valck, D., Beyaert, R., Van Roy, F., and Fiers, W. Tumor necrosis factor cytotoxicity is associated with phospholipase D activation. Eur. J. Biochem., 202: 491-497, 1993.
37. Dealtry, C. B., Naylor, M. S., Fiers, W., and Balkwill, F. R. DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-γ. Eur. J. Immunol., 17: 689-693, 1987.
38. Wrighton, C. J., Hofer-Warbinek, R., Moll, T., Eytner, R., Bach, F. H., and de Martin, R. Inhibition of endothelial cell activation by adenovirus-mediated expression of IkBa, an inhibitor of transcription factor NF-κB. J. Exp. Med., 183: 1013-1022, 1996.
39. Read, M. A., Neish, A. S., Gerritsen, M. E., and Collins, T. Post-induction of transcriptional repression of E-selectin and vascular cell adhesion molecule-1. J. Immunol., 157: 3472-3479, 1996.
40. Akira, S., Taga, T., and Kishimoto, T. Interleukin-6 in biology and medicine. Adv. Immunol., 54: 1-78, 1993.
41. Borsellino, N., Belldegrun, A., and Bonavida, B. Endogenous interleukin 6 is a resistance factor of cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res., 55: 4633-4639, 1995.
42. Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G., Klocker, H., and Culig, Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res., 58: 4640-4645, 1998.
43. Sato, N., Sadar, M., Bruchovsky, N., Saatcioglu, F., and Rennie, P. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J. Biol. Chem., 272: 17485-17494, 1997.